{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > PI3K/Akt/mTOR > CapivasertibCAS：1143532-39-1
Molecular Formula：C21H25ClN6O2
Molecular Weight：428.92
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 1143532-39-1 |
| Name | Capivasertib |
| Molecular Formula | C21H25ClN6O2 |
| Molecular Weight | 428.92 |
| Solubility | Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD22628785 |
| SMILES | O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO |
| Target Point | Akt |
| Passage | PI3K/Akt/mTOR |
| Background | Capivasertib is a potent pan-AKT kinase inhibitor that inhibits Akt1, Akt2 and Akt3. |
| Biological Activity | Capivasertib (AZD5363) 是一种有效的 pan-AKT 激酶抑制剂，抑制 Akt1，Akt2 和 Akt3，IC50 分别为 3，7 和 7 nM。[1] |
| Data Literature Source | [1]. Davies BR，et al. Preclinical pharmacology of AZD5363，an inhibitor of AKT: pharmacodynamics，antitumor activity，and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87 |
| Unit | Bottle |
| Specification | 5mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
